Increased gallium-68 DOTATOC uptake in normal thyroid glands

Hormone and Metabolic Research

Volumn 43, Issue 4, 2011, Pages 282-286

  Lincke, T ^a   Orschekowski, G ^a   Singer, J ^a   Sabri, O ^a   Paschke, R ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Ga 68 DOTATOC; normal thyroid; PET; relative quantification; SSTR; thyroid gland; thyroid nodules

Indexed keywords

GALLIUM 68; THYROTROPIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG UPTAKE; FEMALE; GOITER; HASHIMOTO DISEASE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; NEUROENDOCRINE TUMOR; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SEX DIFFERENCE; THYROID GLAND; THYROID SCINTISCANNING; ULTRASOUND;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MALE; MIDDLE AGED; OCTREOTIDE; ORGANOMETALLIC COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; THYROID DISEASES; THYROID GLAND; YOUNG ADULT;

EID: 79953279073     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0030-1270522     Document Type: Article

References (22)

1. Danila DC, Haidar JN, Zhang X, Katznelson L, Culler MD, Klibanski A. Somatostatin receptor-specific analogs: effects on cell proliferation and growth hormone secretion in human somatotroph tumors. J Clin Endocrinol Metab 2001 86 2976-2981 (Pubitemid 32673451)
2. Krantic S, Goddard I, Saveanu A, Giannetti N, Fombonne J, Cardoso A, Jaquet P, Enjalbert A. Novel modalities of somatostatin actions. Eur J Endocrinol 2004 151 643-655 (Pubitemid 40090005)
3. Becker W, Schrell U, Buchfelder M, Hensen J, Wendler J, Gramatzki M, Wolf F. Somatostatin receptor expression in the thyroid demonstrated with 111In-octreotide scintigraphy. Nuklearmedizin 1995 34 100-103
4. Rambaldi PF, Cuccurullo V, Briganti V, Mansi L. The present and future role of 111In Pentetreotide in the PET era. Q J Nucl Med Mol Imaging 2005 49 225-235 (Pubitemid 41569510)
5. Hofland LJ, Lamberts SW, van Hagen PM, Reubi JC, Schaeffer J, Waaijers M, van Koetsveld PM, Srinivasan A, Krenning EP, Breeman WA. Crucial role for somatostatin receptor subtype 2 in determining the uptake of 111In-DTPA-DPhe1 octreotide in somatostatin receptor-positive organs. J Nucl Med 2003 44 1315-1321 (Pubitemid 39655192)
6. Maecke HR, Hofmann M, Haberkorn U. (68)Ga-labeled peptides in tumor imaging. J Nucl Med 2005 46 172S-178S
7. Koukouraki S, Strauss LG, Georgoulias V, Eisenhut M, Haberkorn U, Dimitrakopoulou-Strauss A. Comparison of the pharmacokinetics of 68Ga-DOTATOC and [18F]FDG in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy. Eur J Nucl Med Mol Imaging 2006 33 1115-1122 (Pubitemid 44484467)
8. Patel YC, Srikant CB. Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hsstr 1-5). Endocrinology 1994 135 2814-2817 (Pubitemid 24377451)
9. Bruns C, Raulf F, Hoyer D, Schloos J, Lübbert H, Weckbecker G. Binding properties of somatostatin receptor subtypes. Metabolism 1996 45 17-20
10. Ain KB, Taylor KD. Somatostatin analogs affect proliferation of human thyroid carcinoma cell lines in vitro. J Clin Endocrinol Metab 1994 78 1097-1102 (Pubitemid 24143030)
11. Medina DL, Toro M-J, Santisteban P. Somatostatin interferes with thyrotropin-induced G1-S transition mediated by cAMP-dependent protein kinase and phosphatidylinositol 3-kinase. Involvement of RhoA and cyclin E x cyclin-dependent kinase 2 complexes. J Biol Chem 2000 275 15549-15556 (Pubitemid 30337289)
12. Lattuada D, Casnici C, Crotta K, Mastrotto C, Franco P, Schmid HA, Marelli O. Inhibitory effect of pasireotide and octreotide on lymphocyte activation. J Neuroimmunol 2007 182 153-159 (Pubitemid 46026714)
13. Medina DL, Velasco JA, Santisteban P. Somatostatin is expressed in FRTL-5 thyroid cells and prevents thyrotropin-mediated down-regulation of the cyclin-dependent kinase inhibitor p27kip1. Endocrinology 1999 140 87-95 (Pubitemid 29011145)
14. Lincke T, Singer J, Kluge R, Sabri O, Paschke R. Relative quantification of In-111 Pentetreotide and Ga-68 DOTATOC uptake in the thyroid gland and association with thyroid pathologies. Thyroid 2009 19 381-389
15. Yüksel M, Eziddin S, Wardelmann E, Biersack HJ. 111In-Pentetreotide uptake in a follicular adenoma of the thyroid gland: a pitfall for 111In-Pentetreotide scintigraphy. Rev Esp Med Nucl 2006 25 316-319 (Pubitemid 44606532)
16. Koriyama N, Nakazaki M, Hashiguchi H, Aso K, Ikeda Y, Kimura T, Eto H, Hirano H, Nakano S, Tei C. Thyrotropin-producing pituitary adenoma associated with Graves' disease. Eur J Endocrinol 2004 151 587-594 (Pubitemid 39562514)
17. Krassas GE, Kahaly GJ. The role of octreoscan in thyroid eye disease. Eur J Endocrinol 1999 140 373-375 (Pubitemid 29253999)
18. Zatelli MC, degli Uberti EC. Somatostatin receptors: from basic science to clinical approach - thyroid. Dig Liver Dis 2004 36 86-92
19. Krummenauer F. Statistics in medical publications: Check lists for Authors. Klin Monbl Augenheilkd 2003 220 362-365 (Pubitemid 36734034)
20. Druckenthaner M, Schwarzer C, Ensinger C, Gabriel M, Prommegger R, Riccabona G, Decristoforo C. Evidence for Somatostatin receptor 2 in thyroid tissue. Regul Pept 2007 138 32-39 (Pubitemid 44918128)
21. Kahaly G, Gorges R, Diaz M, Hommel G, Bockisch A. Indium-111- pentetreotide in Graves' disease. J Nucl Med 1998 39 533-536 (Pubitemid 28136858)
22. Gorancini S, La Rosa S, De Palma D, Uccella S, Golonia F. Uptake of In-111-pentetreotide by normally functioning nodular goiters. Clin Nucl Med 1997 22 625-627 (Pubitemid 28049477)